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A growing body of evidence supports the
hypothesis that exposures that damage or
disrupt the developing central nervous system
are associated with schizophrenia and related
disorders (McGrath and Murray 2003).
Associations for some prenatal exposures have
now been replicated—for example, nutritional
deprivation (St. Clair et al. 2005; Susser et al.
1996). Exposure to potentially neurotoxic
metals has not been carefully examined to
date. In an earlier study, we measured a
marker of second-trimester exposure to lead in
prospectively collected serum samples from a
birth cohort (Opler et al. 2004). The risk for
schizophrenia spectrum disorders in adult-
hood was shown to be approximately doubled
in subjects with maternal blood Pb levels
(BPb) > 15 µg/dL [indicated by elevated levels
of δ-aminolevulinic acid (δ-ALA)] during the
second trimester, although the sample was too
small to draw definitive conclusions and the
results failed to reach statistical signiﬁcance.
There are reasons to suspect that chemical
agents in general, and particularly those associ-
ated with industrialization, may increase the
risk of schizophrenia. Pb is a widely recognized
developmental toxicant, leading to cognitive,
behavioral, and physical impairments.
Prospective birth cohorts in various parts of the
world are consistent in ﬁnding that increased
Pb exposure during development is associated
with decrements in intellectual function up to
10 years of age [for a review, see Lanphear et al.
(2005)]. There is also some suggestion that
effects may persist into early adulthood; for
example, Dietrich et al. (2001) found associa-
tions between elevated prenatal and childhood
BPb concentrations and increased rates of
delinquency during adolescence. 
We designed the present study to expand
our previous work with the Prenatal
Determinants of Schizophrenia (PDS) study.
As in our previous work, we capitalized on a
large birth cohort in which pregnant women
were recruited between 1959 and 1966. In
this report, we used the New England sites of
the National Collaborative Perinatal Project
(NE-NCPP) (McGrath et al. 2003), whose
data and design are similar to those of the
PDS study. Many of the now adult offspring
have been followed for neuropsychiatric out-
comes. In this study, we independently ana-
lyzed these data, which we then pooled with
data from our original work to test the
hypothesis that prenatal Pb exposure is associ-
ated with risk of schizophrenia.
Materials and Methods
Description of cohorts. We obtained data and
serum from two cohorts based in the United
States. a) We included 81 subjects from the
NE-NCPP. The NE-NCPP was part of a
larger, multicenter cohort study initiated by
the National Institute of Neurological and
Communicative Disorders and Stroke, origi-
nally designed to identify associations between
prenatal factors and adverse infant and child
development. The New England cohorts
comprise 17,741 pregnancies collected
prospectively from 1959 to 1966 at the Child
Study Center, Brown University, Providence,
Rhode Island, and the Boston Hospital for
Women and Children, Hospital Medical
Center, Boston (McGrath et al. 2003). b) The
PDS study is based on a cohort of live births
collected prospectively from 1959 through
1967 at the Kaiser Foundation Health Plan
clinics in Alameda County, California, as part
of the Child Health and Development Study.
The PDS study includes the 12,094 live-born
individuals remaining in the health plan until
1981, when it became possible to use comput-
erized records to identify potential cases of
schizophrenia (Susser et al. 2000).
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BACKGROUND: A previously conducted study of prenatal lead exposure and schizophrenia using
δ-aminolevulinic acid, a biologic marker of Pb exposure, in archived maternal serum samples col-
lected from subjects enrolled in the Childhood Health and Development Study (1959–1966) based
in Oakland, California, suggested a possible association between prenatal Pb exposure and the
development of schizophrenia in later life. 
OBJECTIVES: In the present study we extend these ﬁndings using samples collected from the New
England cohort of the National Collaborative Perinatal Project (1959–1966). Using similar meth-
ods, in this study we found results that suggest a comparable association in this cohort. 
METHODS: We pooled matched sets of cases and controls from both the California and New
England sites using a multilevel random-intercept logistic regression model, accounting for match-
ing and site structure as well as adjusting for maternal age at delivery and maternal education. 
RESULTS: The estimated odds ratio for schizophrenia associated with exposure corresponding to
15 µg/dL of blood Pb was 1.92 (95% conﬁdence interval, 1.05–3.87; p = 0.03). 
CONCLUSION: Although several limitations constrain generalizability, these results are consistent
with previous ﬁndings and provide further evidence for the role of early environmental exposures in
the development of adult-onset psychiatric disorders.
KEY WORDS: δ-aminolevulinic acid, developmental, lead, Pb, prenatal, prospective, psychosis, schiz-
ophrenia. Environ Health Perspect 116:1586–1590 (2008). doi:10.1289/ehp.10464 available via
http://dx.doi.org/ [Online 30 July 2008]Case ascertainment. We identified indi-
viduals with major psychosis within the
NE-NCPP cohorts through a two-stage diag-
nostic assessment procedure (Figure 1). In the
ﬁrst stage, we identiﬁed cohort members with
possible psychotic illness through record link-
ages with public hospitals, mental health clin-
ics, and the Massachusetts and Rhode Island
Departments of Mental Health, and from
personal interviews.
Using record linkage and personal inter-
views, we identiﬁed 241 potential cases. In the
second stage, we located these 241 subjects
through a variety of methods, including
searches of credit bureaus, address directories,
death certiﬁcates, motor vehicle reports, and
home visits. Those who consented to partici-
pate in follow-up efforts were interviewed by a
trained interviewer using the Structured
Clinical Interview for the Diagnostic and
Statistical Manual for Mental Disorders, 4th
edition (DSM-IV) (American Psychiatric
Association 2000), to determine lifetime
prevalence of psychotic disorders as well as
other mental disorders. Based on interview
data and medical record review, trained PhD-
and MD-level diagnosticians then completed
best-estimate consensus diagnoses according to
DSM-IV criteria. In the NE-NCPP, diagnos-
tic interviews were completed for 167 subjects;
medical charts alone were available for the
remaining 74 subjects.
We drew the samples used in this study
from subjects with schizophrenic psychoses
and matched controls. Of the 241 potential
subjects with psychosis, 111 subjects were
determined to have a major psychotic disorder.
Of these subjects, 51 were diagnosed with
schizophrenic psychoses [schizophrenia (n =
47) or schizoaffective disorder (n = 4)]. A total
of 27 cases (25 diagnosed with schizophrenia
and 2 diagnosed with schizoaffective disorder)
had serum samples available for this analysis.
For each case subject, we selected two healthy
controls matched for sex, race/ethnicity, and
date of birth. We selected controls from an
unaffected subset of subjects with no Axis I
psychiatric diagnoses.
Overall, procedures for case ascertainment
were similar to those used in the PDS study,
including the use of consensus diagnostic pro-
cedures based on DSM-IV criteria. In the PDS
study, a broader case deﬁnition was used for
schizophrenia spectrum disorder, whereas the
NE-NCPP included only schizophrenia and
schizoaffective disorder. However, matching
criteria for selecting controls in the NE-NCPP
differed from the PDS study. Specifically,
although both the NE-NCPP and PDS study
matched on sex and date of birth, only the
NE-NCPP matched on maternal ethnicity,
and only the PDS study included the length of
time subjects were in the cohort and the avail-
ability of maternal serum.
Serum samples in the NE-NCPP. Women
were registered in their ﬁrst clinic or hospital
visit, and in addition to detailed records on a
variety of demographic characteristics of the
parents and obstetric health, maternal blood
was drawn every trimester and at birth (Buka
et al. 2001). We obtained aliquots of 1 mL of
maternal serum from both cases and controls,
diluted 1:5 in phosphate-buffered saline and
frozen at –20°C. We used third-trimester
samples for 27 cases of schizophrenia spec-
trum disorder and 54 matched controls.
Although seasonal variation has been noted to
cause interindividual variation in third-
trimester BPb levels, published data indicate
that variability between the second- and
third-trimester BPb levels is generally limited.
However, there is some indication that Pb
levels may increase toward the end of the
third trimester. These ﬂuctuations, when cor-
rected using hematocrit levels to account for
the increases in ﬂuid volume, range from 0 to
1 µg/dL (Gulson et al. 2004).
Laboratory protocol for NE-NCPP.
Procedures for analysis of δ-ALA were similar
to those used previously in analysis of samples
from the PDS study. In brief, we thawed
frozen serum samples and centrifuged them
for 30 min at 14,000 rpm at 4°C. We
removed an aliquot of supernatant and added
it to 3.0 mL of acetylacetone reagent and 0.45
mL of 37% formaldehyde. Aliquot volumes
ranged from 50 to 500 µL, based on dilution
and starting volume. We loosely capped tubes
and heated them on an aluminum alloy block
heater in a darkroom for 40 min and then
removed them from the heat to a test tube
rack to cool in the darkroom at room temper-
ature for 4 hr. We removed supernatant from
the test tubes to Eppendorf tubes and cen-
trifuged the tubes for 30 min in a 4°C cool
room. We then filtered the supernatant and
analyzed 750 µL using a PerkinElmer model
LC-250 equipped with an LC-600 autosam-
pler and an LC-40 fluorescence detector
(PerkinElmer, Norwalk, CT) with separation
conditions as previously reported.
Exposure definition and statistical
methods. We classified subjects according to
previously validated methods, that is, having a
BPb of ≥ 15 µg/dL or < 15 µg/dL, based on a
cutoff of 9.05 ng/mL δ-ALA (Opler et al.
2004). As discussed in our prior publication
(Opler et al. 2004), we found this method to
have a moderate correlation (0.64) when used
as a continuous measure, but when used cate-
gorically to predict BPb levels above or below
15 µg/dL, it was highly sensitive (90–91%)
with positive predictive values of 89–91%. A
calculated kappa statistic for duplicate samples
was 0.89 with an SE of 0.23, indicating
excellent agreement.
Using this method and exposure defini-
tion, we ﬁtted conditional logistic regression
models and estimated odds ratios (ORs) relat-
ing exposure status to a diagnosis of schizo-
phrenia spectrum disorder. We combined
results from the NE-NCPP with previously
collected data from a nested sample of 119
subjects (44 cases and 75 controls) from the
PDS study, described in detail elsewhere
(Opler et al. 2004). The combined samples
from the PDS study and NE-NCPP totaled
200 subjects (71 cases and 129 controls). To
examine the relationship between δ-ALA and
schizophrenia spectrum disorders in the com-
bined samples, we used two approaches. First,
we ﬁtted conditional logistic regression mod-
els, including δ-ALA exposure as a predictor of
schizophrenia spectrum disorder, while adjust-
ing for covariates. Next, we ﬁtted a multilevel
random intercept logistic regression model
using generalized linear latent and mixed
models (GLLAMM) software within the
STATA statistical package (StataCorp, College
Station, TX) to account for the multilevel
structure of the data (Rabe-Hesketh et al.
2004). Thus, we took into account the poten-
tial correlations within each “site” (i.e., PDS
study vs. NE-NCPP).
We assessed potential confounders based
on their known association with Pb exposure
and/or schizophrenia, including maternal age
at delivery, paternal age at delivery, parental
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Figure 1. Serum δ-ALA distributions for NE-NCPP (mean ± SD = 11.6 ± 15.21; n = 81) (A) and PDS (mean ±
SD = 9.0 ± 9.80; n = 119) (B) samples. 
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A Bemployment status, maternal education,
maternal race/ethnicity, and paternal educa-
tion. A change of ±10% in the point estimate
corresponding to the Pb exposure variable
provided justiﬁcation for including a variable
in the model. Because we included maternal
race/ethnicity in the matching criteria for the
NE-NCPP sample, we used an indicator vari-
able that coded for this covariate only in the
PDS study.
Results
These cohorts have previously been reported to
differ in terms of several variables, including
ethnicity, maternal age, and education (Strauss
and Dietz 1999). The samples that were
obtained for this study reﬂect these differences
(Table 1). The NE-NCPP cohort was younger,
was less ethnically diverse, and had a higher
proportion of mothers who did not complete
high school. By contrast, the PDS sample was
more ethnically diverse, and most of the moth-
ers in the sample had graduated high school
and/or received further education.
δ-ALA concentrations. As previously
reported, retention times for δ-ALA occurred
within a limited range, consistently near the
mean (± SD) of 9.2 ± 0.36 min. Similar to
previous findings, detectable δ-ALA peaks
were very clear, and chromatograms were
consistently characterized by low baselines
and high signal-to-noise ratios. No other
detectable compounds had retention times or
signals that caused interference with the
δ-ALA peak.
In subjects from the NE-NCPP sample,
δ-ALA levels ranged up to 70.5 ng/mL
(Figure 2A), with a mean (± SD) of 11.6 ±
15.2 ng/mL; the mean concentration in the
PDS study was 9.0 ± 9.8 ng/mL. Despite
some differences in the distribution of δ-ALA
concentrations, a similar proportion of sub-
jects within each sample met the study deﬁni-
tion for Pb exposure (Figure 2B). We
classiﬁed 42% of subjects (n = 34) as exposed
in the NE-NCPP sample and 45% of subjects
as exposed (n = 53) in the PDS sample.
Distribution of covariates by exposure and
case status. We noted differences in distribu-
tions of covariates between sites (Table 1).
Although the NE-NCPP sample demon-
strated no difference in maternal age in
exposed versus unexposed subjects, in the PDS
sample mothers of unexposed subjects were on
average 1 year older than those classified as
exposed. Mean maternal age was higher in
cases than in controls at both sites, but this
was not associated with risk of disease in either
the NE-NCPP sample [OR = 1.01; 95% con-
ﬁdence interval (CI), 0.62–1.64; p = 0.97] or
the PDS sample (OR = 1.1; 95% CI,
0.54–2.4; p = 0.8). Higher maternal age
appears to be associated with lower exposure
levels, although this association is not statisti-
cally significant for either the NE-NCPP
sample (OR = 0.744; 95% CI, 0.25–2.23;
p = 0.6) or the PDS sample (OR = 0.78; 95%
CI, 0.43–1.41; p = 0.4). Higher maternal edu-
cation (i.e., graduation from high school or
equivalent) had a nonsignificant protective
association with case status in the NE-NCPP
sample (OR = 0.49; 95% CI, 0.17–1.38; p =
0.17) and PDS sample (OR = 0.49; 95% CI,
0.19–1.22; p = 0.12). Conversely, the risk of
exposure appears to be higher among subjects
whose mothers completed high school for
both the NE-NCPP sample (OR = 2.08; 95%
CI, 0.84–5.16; p = 0.11) and the PDS sample
(OR = 1.43; 95% CI, 0.57–3.6; p = 0.43).
Estimates of effect size. Table 2 presents
the conditional results from independent and
combined analyses, as both unadjusted and
adjusted effect estimates. With conditional
logistic regression, the unadjusted estimated
OR for schizophrenia in subjects classified
as exposed in the NE-NCPP cohort was
1.58 (95% CI, 0.55–4.51). As previously
reported, a similar unadjusted measure in the
PDS study yields an OR = 1.89 (95% CI,
0.86–4.11). After we combined both samples
into a multilevel, random-intercept logistic
regression model, the estimate of the unad-
justed OR was 1.72 (95% CI, 0.96–3.09).
When adjusted for maternal age and educa-
tion, the estimated OR was 1.92 (95% CI,
1.05–3.52).
We tested several other covariates in
the model including paternal age, paternal
employment status, and maternal race/ethnic-
ity. None of the additional variables tested had
any appreciable impact, deﬁned as a change of
±10% or more on the coefﬁcient of the expo-
sure variable when added to or removed from
the model. In the saturated model, including
all available covariates, the estimated OR for
exposure was 1.96 (95% CI, 1.04–3.69).
Discussion
We have attempted to build on our earlier
study by ﬁrst replicating our previous results in
the NE-NCPP sample and then pooling sub-
jects from two separate cohorts to increase our
sample size. This new study expands on our
preliminary work, further demonstrating a pos-
sible association between Pb exposure during
Opler et al.
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Table 1. Demographic variables in the PDS and
NE-NCPP samples.
Measure PDS (%)a NE-NCPP (%)a
Case status (no.)
SSDb cases 44 27
Matched controls 75 54
Maternal age (years)
0–19 11.4 16
20–29 47.1 67.9
30–39 37 14.8
≥ 40 4.2 1.2
Race
White 47.9 74.1
Black 40.3 25.9
Other 10.1 0
Paternal age (years)
20–29 33.6 51.9
30–39 37.8 27.2
≥ 40 16.8 7.4
Mother’s education
< High school 11.8 43.2
≥ High school  79 54.
Unknown 8.4 2.5
aAll values are percentages except for case status.
bSchizophrenia spectrum disorder, defined in the PDS
study as schizophrenia, schizoaffective disorder, delu-
sional disorder, schizoid personality disorder, or psychosis
not otherwise speciﬁed, and in NE-NCPP as schizophrenia
and schizoaffective disorder. 
Figure 2. Case ascertainment in the NE-NCPP. Abbreviations: Schz, schizophrenia; SchzA, schizoaffective
disorder.
NE-NCPP cohort
n = 17,741 pregnancies
Screened positive
(potential cases)
n = 241
Face-to-face assessment
n = 167
Chart diagnosis
n = 74
Other
diagnosis
n = 131
Schz and SchzA
n = 36
Schz and SchzA
n = 15
Other
diagnosis
n = 59
Total Schz and SchzA cases
n = 51
Total cases with available serum
n = 27development and schizophrenia. When we
adjusted our ﬁndings for covariates, they pro-
vide support for previously reported results,
with consistent effects across individual sites
and in the pooled analysis. Despite some differ-
ences in sample and site characteristics, the
effect sizes ranges from 1.6 to 1.9 (Table 2). In
our samples, elevated prenatal levels of δ-ALA,
the proxy for Pb exposure, is associated with
almost a 2-fold increase in risk for schizophre-
nia spectrum disorder in adulthood.
Although these cohorts differed in some
respects, there were remarkable similarities,
including the birth years, comparability of
serum storage procedures, and methods of case
ascertainment. Nonetheless, our analysis faced
challenges similar to those encountered in
meta-analyses—for example, the need to pool
results from different studies while taking into
account the differences in source populations
and methodologies. Although factoring in
these differences, our analysis also had to pre-
serve the matching structure of each study
sample. The matching criteria for both sam-
ples were similar in some respects, but not
identical: Most notably, the NE-NCPP was
matched on race, whereas the PDS study was
not. It was also extremely important for us not
to use any method that would result in the
loss of any subjects or matched sets, thus
negating the use of extremely limited archived
serum samples. The multilevel, random inter-
cept logistic regression model that we ﬁnally
employed met these requirements accounting
for both site- and matched-set correlations.
A limitation of the previous study, which
also applies here, is the use of δ-ALA to approx-
imate Pb exposure. Because most of the Pb in
blood is contained in erythrocytes, which are
absent in sera, we have measured Pb exposure
indirectly by quantifying the amount of δ-ALA
in each serum sample. δ-ALA, a metabolite in
the heme pathway, normally dimerizes rapidly
in the presence of δ-ALA dehydrase to form
porphobilinogen. However, in Pb-exposed
individuals, δ-ALA levels in serum will be
abnormally high because Pb, a potent inhibitor
of erythrocyte δ-ALA dehydrase activity, pre-
vents dimerization (Secchi et al. 1974). The
laboratory methods we have used are adapted
from standard techniques described by several
researchers (Endo et al. 1993; Oishi et al. 1996)
to determine levels of δ-ALA in plasma and fur-
ther adapted by Tomokuni et al. (1993) for use
on archived serum samples.
We found approximately the same per-
centage of exposed subjects in both samples,
indicating that between 42% and 45% have
estimated BPb levels of ≥ 15 µg/dL. This is
consistent with the somewhat limited litera-
ture on BPb concentrations in women from
samples that are contemporary with the
NE-NCPP and PDS study. A study of prox-
imity to freeways in Los Angeles County,
California, found mean BPb levels of 16.7 ±
7.0 µg/dL for exposed women and 9.9 ± 4.9
µg/dL for unexposed women (Thomas et al.
1967). The NE-NCPP sample had slightly
higher exposure levels than the PDS sample,
as reﬂected in the slightly higher mean δ-ALA
level. Although it might be suspected that this
is attributable to older housing stock built
before the 1950s, thus predating the removal
of Pb-based paint, housing that is likely to
contain Pb-based paint was prevalent (and
continues to be so) both in New England and
in Oakland, California. In particular, the city
of Oakland and Alameda County are known
to contain a very high percentage of houses
with either exterior or interior Pb-based paint
(Centers for Disease Control and Prevention
1992). The work of Meyer et al. (2003)
shows that 50% of existing housing contain-
ing Pb-based paint within the United States
was located in seven states—including
California and Massachusetts. Other unmeas-
ured variables could contribute to differences
in exposure levels between the two sites,
including the state of the home environment
maintenance conditions (Sargent et al. 1997)
and levels of automobile traffic (Rabinowitz
et al. 1984), because these subjects were
recruited before the ban on leaded gasoline.
More detailed information regarding cer-
tain covariates might have been beneﬁcial, but
it is doubtful whether their inclusion would
have made a significant difference in the
results. For example, more specific informa-
tion on the level of exposure to urban environ-
ments (sometimes referred to as “urbanicity”)
would have been desirable. Urbanicity is a sus-
pected risk factor for schizophrenia as well as a
determinant of Pb exposure (Pedersen et al.
2004). Although chemical exposures and
ambient pollutants are more prevalent in
urban settings (Marcelis et al. 1998), work by
Pedersen and Mortensen (2006) suggests that
the association between urbanicity and schizo-
phrenia may not be mediated by exposure to
toxins. A review by Krabbendam and van Os
(2005) argues that because urban-environ-
ment–related cases of schizophrenia are not
associated with neuropsychological impair-
ments or obstetric complications, neurodevel-
opmental mechanisms are less likely to be
involved in the relationship.
Although we cannot entirely rule out the
possibility that our estimates of prenatal Pb
exposure are acting as a marker of the number
of years spent in urban environments before
pregnancy, there are several reasons that
maternal urbanicity is not a likely factor in
our results. Both the NE-NCPP and PDS
samples are derived from cohorts based in
urban centers. Consequently, the level of vari-
ability is likely to be limited, and very few
subjects or parents within either sample are
likely to be classified as anything but urban
residents.
Parental socioeconomic status is another
variable we would have liked to analyze in
more detail. Like urban residence, it is also
associated with elevated prenatal and postna-
tal Pb exposure and has been associated with
schizophrenia in some settings. However,
when analyzed in our previous study, it
proved to have no impact on the results
(Opler et al. 2004). Other potential covariates
that were unavailable for this analysis
included family history of schizophrenia and
obstetric complications.
Thus far, we have hypothesized that
in utero exposure and subsequent changes in
neurodevelopment were the most likely causal
pathway to explain our results. Guilarte (2004)
suggested that Pb exposure is a biologically
plausible risk factor for schizophrenia that may
act via the N-methyl D-aspartate (NMDA)
receptor; indeed, Nihei and Guilarte (2001)
demonstrated experimentally that Pb exposure
may cause changes in the expression and func-
tion of the NMDA receptor. This receptor is
particularly critical for learning and memory
and synaptogenesis during development, and
evidence implicating the role of NMDA and
glutamate in schizophrenia has been mounting
and has now led to the development of new
psychopharmacologic agents (Imre 2007).
Although our results provide additional support
for the theory that Pb may exert developmental
effects via changes in expression and function of
NMDA receptor, new studies will be required
to conﬁrm our ﬁndings. Because in utero expo-
sures are often correlated with exposures during
the life course, these future studies will need to
Prenatal lead and schizophrenia: further evidence
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Table 2. Estimated ORs relating δ-ALA (categorized as ≥ 9.05 and < 9.05 ng/mL) and schizophrenia spectrum disorder using four statistical models.
Cohort Cases Controls Model Estimated OR (95% CI) p-Value
NE-NCPP (Boston/Providence) 27 54 Conditional logistic regression, unadjusted for covariates 1.58 (0.55–4.51) 0.394
PDS (California) 44 75 Conditional logistic regression, unadjusted for covariates 1.89 (0.86–4.11) 0.109
PDS and NE-NCPP (combined) 71 129 Conditional logistic regression, unadjusted for covariates 1.77 (0.94–3.32) 0.074
Random intercept logistic regression, unadjusted for covariates 1.72 (0.96–3.09) 0.071
Conditional logistic regression, adjusted for maternal age and maternal education 2.17 (1.12–4.17) 0.020
Random intercept logistic regression, adjusted for maternal age and maternal education 1.92 (1.05–3.52) 0.035Opler et al.
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take both pre- and postnatal environment into
account (Perrin et al. 2007).
As multiple lines of evidence from epi-
demiology converge, they may offer new tar-
gets for translational research. In our studies,
we used serologic evidence to test the hypoth-
esis that early developmental exposure to a
known toxin was associated with elevated risk
of psychotic disorders in later life. Biologic
mechanisms consistent with our ﬁndings and
with available epidemiologic and clinical evi-
dence might be further investigated using ani-
mal models of exposure and disease, designed
specifically to test potential common path-
ways for schizophrenia.
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